Ren Ken Keyong 4
4 · CASI Pharmaceuticals, Inc. · Filed Jun 21, 2019
Insider Transaction Report
Form 4
Ren Ken Keyong
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1]2019-06-20+51,538→ 51,538 totalExercise: $3.13Exp: 2029-06-20→ Common Stock (51,538 underlying)
Footnotes (1)
- [F1]Stock option award will vest ratably quarterly to the end of the year.
Signature
/s/Cynthia W. Hu, attorney-in-fact for Ken K. Ren|2019-06-21